Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 24, 2025 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference

CORAL GABLES, Fla., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
November 19, 2025 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2025 Deloitte Technology Fast 500™

CORAL GABLES, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
November 18, 2025 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference

CORAL GABLES, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
November 05, 2025 16:06 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Reported Q3 2025 Total Revenues of $148.4 Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA® Raising Full-Year 2025 Total Revenue...
November 04, 2025 16:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Recognized Among BioSpace 2026 Best Places to Work

CORAL GABLES, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
November 04, 2025 01:31 ET | Source: Santhera Pharmaceuticals Holding AG

Fünfjahresdaten zu AGAMREE® (Vamorolon) bei Patienten mit DMD zeigen ein verbessertes Sicherheitsprofil bei vergleichbarer Wirksamkeit wie bei der Standardbehandlung mit Kortikosteroiden

Ad-hoc-Mitteilung gemäss Art. 53 KR Vergleichbare Langzeitwirksamkeit wie bei der Standardtherapie mit Kortikosteroiden über 5 Jahre Normales Wachstum bleibt erhalten, im Gegensatz zur...
November 04, 2025 01:31 ET | Source: Santhera Pharmaceuticals Holding AG

Five-year data of AGAMREE® (vamorolone) in patients with DMD show improved safety profile with comparable effectiveness to standard of care corticosteroids

Ad hoc announcement pursuant to Art. 53 LR Comparable long-term effectiveness to standard of care corticosteroids over 5 years Normal growth maintained, in contrast to growth suppression commonly...
November 04, 2025 01:00 ET | Source: Santhera Pharmaceuticals Holding AG

Fünfjahresdaten zu AGAMREE® (Vamorolon) bei Patienten mit DMD zeigen ein verbessertes Sicherheitsprofil bei vergleichbarer Wirksamkeit wie bei der Standardbehandlung mit Kortikosteroiden

Vergleichbare Langzeitwirksamkeit wie bei der Standardtherapie mit Kortikosteroiden über 5 Jahre Normales Wachstum bleibt erhalten, im Gegensatz zur Wachstumshemmung, die bei der Standardbehandlung...
November 04, 2025 01:00 ET | Source: Santhera Pharmaceuticals Holding AG

Five-year data of AGAMREE® (vamorolone) in patients with DMD show improved safety profile with comparable effectiveness to standard of care corticosteroids

Comparable long-term effectiveness to standard of care corticosteroids over 5 years Normal growth maintained, in contrast to growth suppression commonly seen with standard of care corticosteroids...
November 03, 2025 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals to Participate in Jefferies Global Healthcare Conference

CORAL GABLES, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...